AYTU Stock Analysis
AY
Uncovered
Aytu Biopharma Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 164 full-time employees. The company went IPO on 2017-10-20. The firm is focused on commercializing therapeutics and consumer health products and developing therapeutics for rare pediatric-onset or difficult-to-treat diseases. The company manufactures its products for the treatment of attention deficit hyperactivity disorder (ADHD) at its manufacturing facilities and uses third party manufacturers for its other prescription and consumer health products. The firm operates through two business segments: BioPharma and Consumer Health. The BioPharma segment consists of prescription pharmaceutical products (the Rx Portfolio). The Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The firm also has two product candidates in development, AR101 (enzastaurin) for the treatment of vascular Ehlers-Danlos Syndrome (VEDS) and Healight (endotracheal ultraviolet light catheter) for the treatment of severe, difficult-to-treat respiratory infections.